|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
DE2010115A1
(de)
|
1970-03-04 |
1971-09-16 |
Farbenfabriken Bayer Ag, 5090 Leverkusen |
Verfahren zur Herstellung von Mikrogranulaten
|
|
JPS523342B2
(cg-RX-API-DMAC10.html)
|
1972-01-26 |
1977-01-27 |
|
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4201860A
(en)
|
1978-05-09 |
1980-05-06 |
Bristol-Myers Company |
Purine derivatives
|
|
US4384975A
(en)
|
1980-06-13 |
1983-05-24 |
Sandoz, Inc. |
Process for preparation of microspheres
|
|
US4389330A
(en)
|
1980-10-06 |
1983-06-21 |
Stolle Research And Development Corporation |
Microencapsulation process
|
|
US4415732A
(en)
|
1981-03-27 |
1983-11-15 |
University Patents, Inc. |
Phosphoramidite compounds and processes
|
|
US4426330A
(en)
|
1981-07-20 |
1984-01-17 |
Lipid Specialties, Inc. |
Synthetic phospholipid compounds
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4735935A
(en)
*
|
1985-12-17 |
1988-04-05 |
Carrington Laboratories, Inc. |
Process for preparation of aloe products products, produced thereby and compositions thereof
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
JPS60100516A
(ja)
|
1983-11-04 |
1985-06-04 |
Takeda Chem Ind Ltd |
徐放型マイクロカプセルの製造法
|
|
US5643889A
(en)
|
1984-07-11 |
1997-07-01 |
Temple University-Of The Commonwealth System Of Pennsylvania |
Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
|
|
US5028703A
(en)
|
1988-03-11 |
1991-07-02 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
|
US4810646A
(en)
|
1984-11-28 |
1989-03-07 |
Massachusetts Institute Of Technology |
Glucan compositions and process for preparation thereof
|
|
US4992540A
(en)
|
1984-11-28 |
1991-02-12 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
|
US5082936A
(en)
|
1984-11-28 |
1992-01-21 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
DE3529497A1
(de)
|
1985-08-17 |
1987-02-26 |
Boehringer Mannheim Gmbh |
N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
EP0260032B1
(en)
|
1986-09-08 |
1994-01-26 |
Ajinomoto Co., Inc. |
Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
|
|
US6005094A
(en)
|
1986-10-28 |
1999-12-21 |
Genta Incorporated |
Oligonucleotide analogues having improved stability at acid pH
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US4904582A
(en)
|
1987-06-11 |
1990-02-27 |
Synthetic Genetics |
Novel amphiphilic nucleic acid conjugates
|
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5525465A
(en)
|
1987-10-28 |
1996-06-11 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Oligonucleotide-polyamide conjugates and methods of production and applications of the same
|
|
DE3738460A1
(de)
|
1987-11-12 |
1989-05-24 |
Max Planck Gesellschaft |
Modifizierte oligonukleotide
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5750666A
(en)
|
1988-05-26 |
1998-05-12 |
Competitve Technologies, Inc. |
Polynucleotide phosphorodithioate compounds
|
|
US5149782A
(en)
|
1988-08-19 |
1992-09-22 |
Tanox Biosystems, Inc. |
Molecular conjugates containing cell membrane-blending agents
|
|
US5512439A
(en)
|
1988-11-21 |
1996-04-30 |
Dynal As |
Oligonucleotide-linked magnetic particles and uses thereof
|
|
US5354844A
(en)
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
|
WO1990013361A1
(en)
|
1989-05-04 |
1990-11-15 |
Southern Research Institute |
Improved encapsulation process and products therefrom
|
|
US5051257A
(en)
|
1989-05-09 |
1991-09-24 |
Pietronigro Dennis D |
Antineoplastic solution and method for treating neoplasms
|
|
US5162115A
(en)
|
1989-05-09 |
1992-11-10 |
Pietronigro Dennis D |
Antineoplastic solution and method for treating neoplasms
|
|
ZA902710B
(en)
|
1989-05-22 |
1991-12-24 |
Univ Georgia Res Found |
Enzyme luminescence assay
|
|
US4958013A
(en)
|
1989-06-06 |
1990-09-18 |
Northwestern University |
Cholesteryl modified oligonucleotides
|
|
US5032401A
(en)
|
1989-06-15 |
1991-07-16 |
Alpha Beta Technology |
Glucan drug delivery system and adjuvant
|
|
US5227170A
(en)
|
1989-06-22 |
1993-07-13 |
Vestar, Inc. |
Encapsulation process
|
|
JPH0383914A
(ja)
|
1989-08-18 |
1991-04-09 |
W R Grace & Co |
ドラッグキャリアー
|
|
EP0490995A1
(en)
|
1989-09-08 |
1992-06-24 |
Alpha Beta Technology |
Method for producing soluble glucans
|
|
ATE153856T1
(de)
|
1989-09-08 |
1997-06-15 |
Alpha Beta Technology |
Zusammensetzung zur stimulierung des immunsystems
|
|
US5591722A
(en)
|
1989-09-15 |
1997-01-07 |
Southern Research Institute |
2'-deoxy-4'-thioribonucleosides and their antiviral activity
|
|
US5356633A
(en)
|
1989-10-20 |
1994-10-18 |
Liposome Technology, Inc. |
Method of treatment of inflamed tissues
|
|
US5527528A
(en)
|
1989-10-20 |
1996-06-18 |
Sequus Pharmaceuticals, Inc. |
Solid-tumor treatment method
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
WO1991006556A1
(en)
|
1989-10-24 |
1991-05-16 |
Gilead Sciences, Inc. |
2' modified oligonucleotides
|
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
|
US5495009A
(en)
|
1989-10-24 |
1996-02-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs containing thioformacetal linkages
|
|
US5469854A
(en)
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
|
US5580575A
(en)
|
1989-12-22 |
1996-12-03 |
Imarx Pharmaceutical Corp. |
Therapeutic drug delivery systems
|
|
US5486603A
(en)
|
1990-01-08 |
1996-01-23 |
Gilead Sciences, Inc. |
Oligonucleotide having enhanced binding affinity
|
|
US5514786A
(en)
|
1990-01-11 |
1996-05-07 |
Isis Pharmaceuticals, Inc. |
Compositions for inhibiting RNA activity
|
|
US5646265A
(en)
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
|
US6358931B1
(en)
|
1990-01-11 |
2002-03-19 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating RNA
|
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
|
US6395492B1
(en)
|
1990-01-11 |
2002-05-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US6153737A
(en)
|
1990-01-11 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
US5670633A
(en)
|
1990-01-11 |
1997-09-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
|
WO1991013080A1
(en)
|
1990-02-20 |
1991-09-05 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
|
US5658731A
(en)
|
1990-04-09 |
1997-08-19 |
Europaisches Laboratorium Fur Molekularbiologie |
2'-O-alkylnucleotides as well as polymers which contain such nucleotides
|
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
|
AU7979491A
(en)
|
1990-05-03 |
1991-11-27 |
Vical, Inc. |
Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
|
|
CA2040374C
(en)
|
1990-07-06 |
1998-06-16 |
Gunnar Rorstad |
Process for enhancing the resistance of aquatic animals to disease
|
|
US5386023A
(en)
|
1990-07-27 |
1995-01-31 |
Isis Pharmaceuticals |
Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
|
|
JPH0874B2
(ja)
|
1990-07-27 |
1996-01-10 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
ES2259177T3
(es)
|
1990-08-13 |
2006-09-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotidos modificados en el azucar que detectan y modulan la expresion genica.
|
|
JP3256539B2
(ja)
|
1990-08-28 |
2002-02-12 |
エポック・ファーマシューティカルズ・インコーポレイテッド |
連結分子を介する３’―尾分子付オリゴヌクレオチドの固体支持体合成
|
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
|
US5561225A
(en)
|
1990-09-19 |
1996-10-01 |
Southern Research Institute |
Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
|
|
WO1992005186A1
(en)
|
1990-09-20 |
1992-04-02 |
Gilead Sciences |
Modified internucleoside linkages
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
GB9022560D0
(en)
|
1990-10-17 |
1990-11-28 |
G B Biotechnology Limited |
Processing of waste
|
|
WO1994008003A1
(en)
|
1991-06-14 |
1994-04-14 |
Isis Pharmaceuticals, Inc. |
ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
|
|
JP3220180B2
(ja)
|
1991-05-23 |
2001-10-22 |
三菱化学株式会社 |
薬剤含有タンパク質結合リポソーム
|
|
US5419966A
(en)
|
1991-06-10 |
1995-05-30 |
Microprobe Corporation |
Solid support for synthesis of 3'-tailed oligonucleotides
|
|
US5214135A
(en)
|
1991-08-30 |
1993-05-25 |
Chemgenes Corporation |
N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides
|
|
US5525719A
(en)
|
1991-08-30 |
1996-06-11 |
Chemgenes Corporation |
N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
|
|
NZ244306A
(en)
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
|
US5599797A
(en)
|
1991-10-15 |
1997-02-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5607923A
(en)
|
1991-10-15 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
|
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
TW393513B
(en)
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
|
US5359044A
(en)
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
|
US5856455A
(en)
|
1991-12-24 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Gapped 2'-modified oligonucleotides
|
|
NZ245720A
(en)
|
1992-01-22 |
1995-12-21 |
Hoechst Ag |
Oligonucleotide analogues; use as gene expression inhibitor or dna probe
|
|
US6113946A
(en)
|
1992-04-03 |
2000-09-05 |
The Regents Of The University Of California |
Self-assembling polynucleotide delivery system comprising dendrimer polycations
|
|
US5633360A
(en)
|
1992-04-14 |
1997-05-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs capable of passive cell membrane permeation
|
|
US5817781A
(en)
|
1992-06-01 |
1998-10-06 |
Gilead Sciences, Inc. |
Modified internucleoside linkages (II)
|
|
EP0577558A2
(de)
|
1992-07-01 |
1994-01-05 |
Ciba-Geigy Ag |
Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
|
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
|
US5583020A
(en)
|
1992-11-24 |
1996-12-10 |
Ribozyme Pharmaceuticals, Inc. |
Permeability enhancers for negatively charged polynucleotides
|
|
US5574142A
(en)
|
1992-12-15 |
1996-11-12 |
Microprobe Corporation |
Peptide linkers for improved oligonucleotide delivery
|
|
JP3351476B2
(ja)
|
1993-01-22 |
2002-11-25 |
三菱化学株式会社 |
リン脂質誘導体及びそれを含有するリポソーム
|
|
US5395619A
(en)
|
1993-03-03 |
1995-03-07 |
Liposome Technology, Inc. |
Lipid-polymer conjugates and liposomes
|
|
NZ263985A
(en)
|
1993-03-31 |
1997-07-27 |
Hybridon Inc |
Oligonucleotide complementary to an essential amino acid sequence of influenza virus
|
|
HU9501974D0
(en)
|
1993-03-31 |
1995-09-28 |
Sterling Winthrop Inc |
Oligonucleotides with amide linkages replacing phosphodiester linkages
|
|
FR2705099B1
(fr)
|
1993-05-12 |
1995-08-04 |
Centre Nat Rech Scient |
Oligonucléotides phosphorothioates triesters et procédé de préparation.
|
|
ES2128535T3
(es)
|
1993-05-12 |
1999-05-16 |
Novartis Ag |
Nucleosidos y oligonucleotidos con grupos 2'-eter.
|
|
US6015886A
(en)
|
1993-05-24 |
2000-01-18 |
Chemgenes Corporation |
Oligonucleotide phosphate esters
|
|
US5580972A
(en)
|
1993-06-14 |
1996-12-03 |
Nexstar Pharmaceuticals, Inc. |
Purine nucleoside modifications by palladium catalyzed methods
|
|
US5428149A
(en)
|
1993-06-14 |
1995-06-27 |
Washington State University Research Foundation |
Method for palladium catalyzed carbon-carbon coulping and products
|
|
US5534259A
(en)
|
1993-07-08 |
1996-07-09 |
Liposome Technology, Inc. |
Polymer compound and coated particle composition
|
|
US5532130A
(en)
|
1993-07-20 |
1996-07-02 |
Dyad Pharmaceutical Corporation |
Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
|
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
|
US5417978A
(en)
|
1993-07-29 |
1995-05-23 |
Board Of Regents, The University Of Texas System |
Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
|
|
US5614621A
(en)
|
1993-07-29 |
1997-03-25 |
Isis Pharmaceuticals, Inc. |
Process for preparing oligonucleotides using silyl-containing diamino phosphorous reagents
|
|
EP1253199A1
(en)
|
1993-09-02 |
2002-10-30 |
Ribozyme Pharmaceuticals, Inc. |
Abasic moieties containing enzymatic nucleic acids
|
|
CA2170869C
(en)
|
1993-09-03 |
1999-09-14 |
Phillip Dan Cook |
Amine-derivatized nucleosides and oligonucleosides
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
GB9320782D0
(en)
|
1993-10-08 |
1993-12-01 |
Univ Leeds Innovations Ltd |
Stabilising of proteins on solution
|
|
ATE174600T1
(de)
|
1993-10-27 |
1999-01-15 |
Ribozyme Pharm Inc |
2'-amido-und 2'-peptido-modifizierte oligonukleotide
|
|
WO1995014031A1
(en)
*
|
1993-11-16 |
1995-05-26 |
Genta Incorporated |
Chirally enriched synthetic phosphonate oligomers
|
|
NZ277616A
(en)
|
1993-11-16 |
1997-12-19 |
Genta Inc |
Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphate internucleosidyl linkages
|
|
US5652359A
(en)
|
1993-12-02 |
1997-07-29 |
Epoch Pharmaceuticals, Inc. |
Oligonucleotides containing n-methyl thiolated bases having antiviral activity
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
JPH09509181A
(ja)
|
1994-02-18 |
1997-09-16 |
ハイブリドン，インコーポレーテッド |
抗呼吸器合胞体ウイルス活性を有するオリゴヌクレオチド
|
|
US5646126A
(en)
|
1994-02-28 |
1997-07-08 |
Epoch Pharmaceuticals |
Sterol modified oligonucleotide duplexes having anticancer activity
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5651981A
(en)
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
|
US5543152A
(en)
|
1994-06-20 |
1996-08-06 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
|
US5777153A
(en)
|
1994-07-08 |
1998-07-07 |
Gilead Sciences, Inc. |
Cationic lipids
|
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
|
US5837533A
(en)
|
1994-09-28 |
1998-11-17 |
American Home Products Corporation |
Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
|
|
US5591721A
(en)
|
1994-10-25 |
1997-01-07 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US5681940A
(en)
|
1994-11-02 |
1997-10-28 |
Icn Pharmaceuticals |
Sugar modified nucleosides and oligonucleotides
|
|
US5512295A
(en)
|
1994-11-10 |
1996-04-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synthetic liposomes for enhanced uptake and delivery
|
|
US5767099A
(en)
|
1994-12-09 |
1998-06-16 |
Genzyme Corporation |
Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
|
|
US5948767A
(en)
|
1994-12-09 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphile/DNA complexes
|
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
|
AUPN166195A0
(en)
|
1995-03-13 |
1995-04-06 |
Norvet Research Pty Limited |
Process for glucan extraction
|
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
WO1996040961A1
(en)
|
1995-06-07 |
1996-12-19 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
|
US5851548A
(en)
|
1995-06-07 |
1998-12-22 |
Gen-Probe Incorporated |
Liposomes containing cationic lipids and vitamin D
|
|
US6221911B1
(en)
|
1995-06-07 |
2001-04-24 |
Karo Bio Ab |
Uses for thyroid hormone compounds or thyroid hormone-like compounds
|
|
JP4335310B2
(ja)
|
1995-06-07 |
2009-09-30 |
ザ ユニバーシティ オブ ブリティッシュ コロンビア |
疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
|
|
AUPN398295A0
(en)
|
1995-07-05 |
1995-07-27 |
Carlton And United Breweries Limited |
Chemical compounds and processes for their production
|
|
US5672662A
(en)
|
1995-07-07 |
1997-09-30 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
|
|
US5734041A
(en)
|
1995-10-20 |
1998-03-31 |
Mcgill University |
Preparation of chiral phosphorothioate oligomers
|
|
US5705621A
(en)
|
1995-11-17 |
1998-01-06 |
Isis Pharmaceuticals, Inc. |
Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same
|
|
US6344436B1
(en)
|
1996-01-08 |
2002-02-05 |
Baylor College Of Medicine |
Lipophilic peptides for macromolecule delivery
|
|
US5684143A
(en)
|
1996-02-21 |
1997-11-04 |
Lynx Therapeutics, Inc. |
Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
|
|
US6331617B1
(en)
|
1996-03-21 |
2001-12-18 |
University Of Iowa Research Foundation |
Positively charged oligonucleotides as regulators of gene expression
|
|
US6444806B1
(en)
|
1996-04-30 |
2002-09-03 |
Hisamitsu Pharmaceutical Co., Inc. |
Conjugates and methods of forming conjugates of oligonucleotides and carbohydrates
|
|
US20080119427A1
(en)
|
1996-06-06 |
2008-05-22 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6506564B1
(en)
|
1996-07-29 |
2003-01-14 |
Nanosphere, Inc. |
Nanoparticles having oligonucleotides attached thereto and uses therefor
|
|
US5789416B1
(en)
|
1996-08-27 |
1999-10-05 |
Cv Therapeutics Inc |
N6 mono heterocyclic substituted adenosine derivatives
|
|
US6111085A
(en)
|
1996-09-13 |
2000-08-29 |
Isis Pharmaceuticals, Inc. |
Carbamate-derivatized nucleosides and oligonucleosides
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
FR2755976B1
(fr)
|
1996-11-15 |
1999-01-15 |
Idm Immuno Designed Molecules |
Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
|
|
US6248878B1
(en)
|
1996-12-24 |
2001-06-19 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside analogs
|
|
CA2289702C
(en)
|
1997-05-14 |
2008-02-19 |
Inex Pharmaceuticals Corp. |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
|
WO1999001579A1
(en)
|
1997-07-01 |
1999-01-14 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
|
AU741546B2
(en)
|
1997-07-24 |
2001-12-06 |
Perseptive Biosystems, Inc. |
Conjugates of transporter peptides and nucleic acid analogs, and their use
|
|
NZ503334A
(en)
|
1997-09-15 |
2002-05-31 |
Genetic Immunity Llc |
A gene delivering complex having a vector with a specific affinity for a foreign genetic material and a second site having a specific affinity for a receptor on an antigen presenting cell
|
|
US20020006913A1
(en)
*
|
1997-11-04 |
2002-01-17 |
Von Borstel Reid W. |
Antimutagenic compositions for treatment and prevention of photodamage to skin
|
|
US6028183A
(en)
|
1997-11-07 |
2000-02-22 |
Gilead Sciences, Inc. |
Pyrimidine derivatives and oligonucleotides containing same
|
|
ATE401312T1
(de)
|
1997-12-15 |
2008-08-15 |
Astellas Pharma Inc |
Pyrimidin-5-carboxamid-derivate
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
US6020475A
(en)
|
1998-02-10 |
2000-02-01 |
Isis Pharmeuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
|
CA2326823A1
(en)
|
1998-04-20 |
1999-10-28 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
|
CA2329130A1
(en)
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
|
US20040241845A1
(en)
|
1998-05-22 |
2004-12-02 |
Luc Desgroseillers |
Mammalian staufen and use thereof
|
|
US6300319B1
(en)
|
1998-06-16 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Targeted oligonucleotide conjugates
|
|
US6277967B1
(en)
|
1998-07-14 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
ATE237312T1
(de)
|
1998-07-20 |
2003-05-15 |
Protiva Biotherapeutics Inc |
In liposomen verkapselte nukleinsäurekomplexe
|
|
US6271358B1
(en)
|
1998-07-27 |
2001-08-07 |
Isis Pharmaceuticals, Inc. |
RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
|
|
US20040009938A1
(en)
|
1998-08-07 |
2004-01-15 |
Muthiah Manoharan |
Methods of enhancing renal uptake of oligonucleotides
|
|
US6043352A
(en)
|
1998-08-07 |
2000-03-28 |
Isis Pharmaceuticals, Inc. |
2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
|
|
US6020483A
(en)
|
1998-09-25 |
2000-02-01 |
Nexstar Pharmaceuticals, Inc. |
Nucleoside modifications by palladium catalyzed methods
|
|
US6455586B1
(en)
|
1998-12-15 |
2002-09-24 |
Leonard L. Kaplan |
Topical immunomodulating compositions for treatment of aids, Hepatitis B & C, other infectious diseases, and cancer
|
|
US7098190B1
(en)
*
|
1999-01-27 |
2006-08-29 |
Coda Therapeutics Ltd. |
Formulations comprising antisense nucleotides to connexins
|
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
US6465628B1
(en)
|
1999-02-04 |
2002-10-15 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
|
US6207819B1
(en)
|
1999-02-12 |
2001-03-27 |
Isis Pharmaceuticals, Inc. |
Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
|
|
BRPI0008131B8
(pt)
|
1999-02-12 |
2021-05-25 |
Daiichi Sankyo Co Ltd |
composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
|
|
AU3243300A
(en)
|
1999-02-23 |
2000-09-14 |
Isis Pharmaceuticals, Inc. |
Multiparticulate formulation
|
|
US6121437A
(en)
|
1999-03-16 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Phosphate and thiophosphate protecting groups
|
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
|
GB9925459D0
(en)
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
|
US8017742B2
(en)
|
1999-11-10 |
2011-09-13 |
Japan Science And Technology Agency |
Gene carrier
|
|
JP2001206899A
(ja)
|
1999-11-18 |
2001-07-31 |
Japan Tobacco Inc |
ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
|
|
US20040072785A1
(en)
|
1999-11-23 |
2004-04-15 |
Wolff Jon A. |
Intravascular delivery of non-viral nucleic acid
|
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
US7098030B2
(en)
|
1999-12-31 |
2006-08-29 |
Mirus Bio Corporation |
Polyampholytes for delivering polyions to a cell
|
|
US20050032733A1
(en)
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
JP2003526367A
(ja)
|
2000-03-16 |
2003-09-09 |
ジェネティカ インコーポレイテッド |
Ｒｎａ干渉の方法とｒｎａ干渉組成物
|
|
KR20080023768A
(ko)
|
2000-03-30 |
2008-03-14 |
화이트헤드 인스티튜트 포 바이오메디칼 리서치 |
Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
|
|
US7108721B2
(en)
|
2000-05-11 |
2006-09-19 |
Massachusetts Institute Of Technology |
Tissue regrafting
|
|
JP5154728B2
(ja)
|
2000-07-24 |
2013-02-27 |
クレニツキー・ファーマシューティカルズ，インコーポレイテッド |
神経栄養活性を有する置換５−アルキニルピリミジン
|
|
EP1414865B1
(en)
|
2000-08-03 |
2014-04-09 |
Abac R & D Ag |
Isolation of glucan particles and uses thereof
|
|
US6559279B1
(en)
|
2000-09-08 |
2003-05-06 |
Isis Pharmaceuticals, Inc. |
Process for preparing peptide derivatized oligomeric compounds
|
|
US6794137B2
(en)
|
2000-09-08 |
2004-09-21 |
New York University |
Gene markers useful for detecting skin damage in response to ultraviolet radiation
|
|
US20020081736A1
(en)
|
2000-11-03 |
2002-06-27 |
Conroy Susan E. |
Nucleic acid delivery
|
|
US6476003B1
(en)
|
2000-11-06 |
2002-11-05 |
Immusonic, Inc. |
Method for preparing small particle size glucan in a dry material
|
|
US20020132788A1
(en)
|
2000-11-06 |
2002-09-19 |
David Lewis |
Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
|
|
CN100523215C
(zh)
|
2000-12-01 |
2009-08-05 |
马普科技促进协会 |
介导rna干涉的小rna分子
|
|
FR2818642B1
(fr)
|
2000-12-26 |
2005-07-15 |
Hoechst Marion Roussel Inc |
Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
|
|
JP2004532616A
(ja)
|
2000-12-28 |
2004-10-28 |
ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド |
二本鎖ｒｎａ仲介遺伝子抑制
|
|
DE10100127A1
(de)
|
2001-01-03 |
2002-10-02 |
Henkel Kgaa |
Verfahren zur Bestimmung der Homeostase der Haut
|
|
US7507724B2
(en)
|
2001-01-16 |
2009-03-24 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
|
US7906492B2
(en)
|
2001-01-16 |
2011-03-15 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
|
US7044945B2
(en)
|
2001-03-30 |
2006-05-16 |
Sand Bruce J |
Prevention of regression in thermal ciliary muscle tendinoplasty
|
|
WO2002087541A1
(en)
|
2001-04-30 |
2002-11-07 |
Protiva Biotherapeutics Inc. |
Lipid-based formulations for gene transfer
|
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US20070173473A1
(en)
|
2001-05-18 |
2007-07-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
|
|
US20070032441A1
(en)
|
2001-05-18 |
2007-02-08 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
|
|
US20030158403A1
(en)
|
2001-07-03 |
2003-08-21 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant chimeric oligonucleotides
|
|
DE10133858A1
(de)
|
2001-07-12 |
2003-02-06 |
Aventis Pharma Gmbh |
Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
|
|
WO2003012052A2
(en)
|
2001-07-30 |
2003-02-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Specific inhibition of gene expression by small double stranded rnas
|
|
US7786094B2
(en)
|
2001-10-09 |
2010-08-31 |
Biopolymer Engineering, Inc. |
Use of beta-glucans against biological warfare weapons and pathogens including anthrax
|
|
JP2005527639A
(ja)
|
2001-11-02 |
2005-09-15 |
インサート セラピューティクス インコーポレイテッド |
Ｒｎａ干渉の治療的利用のための方法及び組成物
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
US20040087526A1
(en)
|
2001-11-12 |
2004-05-06 |
Shi-Lung Lin |
Therapeutically useful compositions of DNA-RNA hybrid duplex constructs
|
|
DK1470144T3
(da)
|
2002-02-01 |
2009-04-06 |
Univ Mcgill |
Oligonukleotider omfattende alternerende segmenter og anvendelser deraf
|
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
|
EP1478656B1
(en)
|
2002-02-01 |
2009-09-16 |
Life Technologies Corporation |
Oligonucleotide compositions with enhanced efficiency
|
|
US20030166282A1
(en)
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
|
US20050222061A1
(en)
|
2002-04-18 |
2005-10-06 |
Schulte Ralf W |
Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
|
|
WO2003099840A1
(en)
|
2002-05-24 |
2003-12-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
|
FR2840217B1
(fr)
|
2002-06-03 |
2005-06-24 |
Oreal |
Compositions cosmetiques comprenant au moins un oligonucleotide d'arn double brin (dsrna)et leurs utilisations
|
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
|
EP1857547B2
(en)
|
2002-08-05 |
2020-12-02 |
Silence Therapeutics GmbH |
Further novel forms of interfering RNA molecules
|
|
DE10238298A1
(de)
*
|
2002-08-21 |
2004-03-04 |
Beiersdorf Ag |
Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen
|
|
EP1546344A4
(en)
|
2002-09-18 |
2007-10-03 |
Isis Pharmaceuticals Inc |
EFFICIENT PRODUCTION OF TARGET RNAS USING SINGLE AND DOUBLE-STRONG OLIGOMER COMPOUNDS
|
|
WO2004029212A2
(en)
|
2002-09-25 |
2004-04-08 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable sirna
|
|
EP1658304A4
(en)
|
2002-09-28 |
2009-01-14 |
Massachusetts Inst Technology |
THERAPY ANTIGRIPPALE
|
|
WO2004042024A2
(en)
|
2002-11-01 |
2004-05-21 |
The Trustees Of The University Of Pennsylvania |
COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA
|
|
AU2003290586B2
(en)
|
2002-11-04 |
2009-07-02 |
University Of Massachusetts |
Allele-specific RNA interference
|
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
EP2305813A3
(en)
|
2002-11-14 |
2012-03-28 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
DE10254214A1
(de)
|
2002-11-20 |
2004-06-09 |
Beiersdorf Ag |
Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
|
|
WO2004048545A2
(en)
|
2002-11-26 |
2004-06-10 |
University Of Massachusetts |
DELIVERY OF siRNAs______________________________________________
|
|
JP2007524349A
(ja)
|
2003-01-16 |
2007-08-30 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
ＩＣＡＭ−１のｓｉＲＮＡ阻害のための組成物及び方法
|
|
WO2004065600A2
(en)
|
2003-01-17 |
2004-08-05 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Rna interference by palindromic or modified rna molecules
|
|
JP2006516288A
(ja)
|
2003-01-21 |
2006-06-29 |
アーケミックス コーポレイション |
眼の薬物療法において有用なアプタマー治療薬
|
|
DE10302421A1
(de)
|
2003-01-21 |
2004-07-29 |
Ribopharma Ag |
Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
|
|
AU2004211949A1
(en)
|
2003-02-05 |
2004-08-26 |
University Of Massachusetts |
RNAi targeting of viruses
|
|
US20040162235A1
(en)
|
2003-02-18 |
2004-08-19 |
Trubetskoy Vladimir S. |
Delivery of siRNA to cells using polyampholytes
|
|
US20040167090A1
(en)
|
2003-02-21 |
2004-08-26 |
Monahan Sean D. |
Covalent modification of RNA for in vitro and in vivo delivery
|
|
EP1604012A2
(en)
|
2003-03-05 |
2005-12-14 |
The Board of Trustees of The Leland Stanford Junior University |
METHODS AND COMPOSITIONS FOR SELECTIVE RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMAL CELLS
|
|
CA2518475C
(en)
|
2003-03-07 |
2014-12-23 |
Alnylam Pharmaceuticals, Inc. |
Irna agents comprising asymmetrical modifications
|
|
EP1608733B1
(en)
|
2003-04-02 |
2011-12-07 |
Dharmacon, Inc. |
Modified polynucleotides for use in rna interference
|
|
US20070167384A1
(en)
|
2003-04-02 |
2007-07-19 |
Dharmacon, Inc. |
Modified polynucleotides for use in rna interference
|
|
EP2669377A3
(en)
|
2003-04-17 |
2015-10-14 |
Alnylam Pharmaceuticals Inc. |
Modified iRNA agents
|
|
AU2004233043A1
(en)
|
2003-04-18 |
2004-11-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2
|
|
US7462602B2
(en)
|
2003-05-01 |
2008-12-09 |
University Of Florida Research Foundation, Inc. |
Anti-scarring ribozymes and methods
|
|
US20060178327A1
(en)
|
2003-05-30 |
2006-08-10 |
Yeung Wah Hin A |
Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
CA2527958C
(en)
|
2003-06-02 |
2014-04-08 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of rnai
|
|
US7405274B2
(en)
|
2003-06-04 |
2008-07-29 |
Fibrogen, Inc. |
Connective tissue growth factor antibodies
|
|
ES2905724T3
(es)
|
2003-06-13 |
2022-04-11 |
Alnylam Europe Ag |
Acido ribonucleico bicatenario con elevada eficacia en un organismo
|
|
US20050026823A1
(en)
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
|
AU2004257373B2
(en)
|
2003-07-16 |
2011-03-24 |
Arbutus Biopharma Corporation |
Lipid encapsulated interfering RNA
|
|
US20050106594A1
(en)
|
2003-08-22 |
2005-05-19 |
Andrew Ellington |
In vitro selection of aptamer beacons
|
|
EP1668144B1
(en)
|
2003-09-11 |
2011-08-17 |
Universitätsklinikum Schleswig-Holstein Campus Lübeck |
Nucleotide sequences promoting the trans-membrane transport of nucleic acids
|
|
CN1882693B
(zh)
|
2003-09-15 |
2012-08-15 |
普洛体维生物治疗公司 |
聚乙二醇修饰的脂质化合物及其应用
|
|
AU2004293474B2
(en)
|
2003-11-24 |
2010-12-23 |
Canji, Inc. |
Reduction of dermal scarring
|
|
US8119791B2
(en)
|
2003-12-17 |
2012-02-21 |
Avon Products, Inc. |
si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation
|
|
MXPA06007269A
(es)
|
2003-12-23 |
2007-07-09 |
Univ Pennsylvania |
Composiciones y metodos para terapia combinada de enfermedad.
|
|
WO2005078094A2
(en)
|
2004-02-06 |
2005-08-25 |
Dharmacon, Inc. |
Stabilized rnas as transfection controls and silencing reagents
|
|
US20060069050A1
(en)
|
2004-02-17 |
2006-03-30 |
University Of Massachusetts |
Methods and compositions for mediating gene silencing
|
|
US20080071068A1
(en)
|
2004-02-20 |
2008-03-20 |
Hideki Oba |
Cytoplasmic Localization Dna and Rna
|
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
|
US20050265957A1
(en)
|
2004-04-08 |
2005-12-01 |
Monahan Sean D |
Polymerized formamides for use in delivery of compounds to cells
|
|
CA2564616C
(en)
|
2004-04-20 |
2016-08-30 |
Nastech Pharmaceutical Company Inc. |
Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
|
|
US8168600B2
(en)
|
2004-04-23 |
2012-05-01 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
|
NZ551644A
(en)
|
2004-05-20 |
2010-06-25 |
Eden Research Plc |
Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them
|
|
CA2569664C
(en)
|
2004-06-07 |
2013-07-16 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
|
US7740861B2
(en)
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
|
JP4971609B2
(ja)
|
2004-08-27 |
2012-07-11 |
アンジェスＭｇ株式会社 |
核酸皮膚外用製剤
|
|
US20060211766A1
(en)
|
2004-09-30 |
2006-09-21 |
Kaplan Leonard L |
Gelled immunomodulating topical compositions and a method of treating warts and other human papilloma virus skin infections
|
|
EP1796732B1
(en)
|
2004-10-01 |
2013-10-30 |
Novartis Vaccines and Diagnostics, Inc. |
Modified small interfering rna molecules and methods of use
|
|
US20100069620A1
(en)
|
2004-12-02 |
2010-03-18 |
Rxi Pharmaceuticals Corp. |
Novel compositions of chemically modified small interfering rna
|
|
JP2008524339A
(ja)
|
2004-12-15 |
2008-07-10 |
メルク エンド カムパニー インコーポレーテッド |
Ａｋｔ活性のインヒビター
|
|
US20060142228A1
(en)
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
|
WO2006092795A2
(en)
|
2005-03-01 |
2006-09-08 |
Qbi Enterprises Ltd. |
Oligoribonucleotides and methods of use thereof for treatment of ocular scarring and other fibrotic conditions
|
|
US8895717B2
(en)
|
2005-04-15 |
2014-11-25 |
The Board Of Regents Of The University Of Texas System |
Delivery of siRNA by neutral lipid compositions
|
|
EP1891217A2
(en)
|
2005-05-27 |
2008-02-27 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of stromal cell-derived factor-1 (sdf-1) gene expression using short interfering nucleic acid (sina)
|
|
EP1888033B1
(en)
|
2005-06-09 |
2014-02-19 |
Meda AB |
Method and composition for treating inflammatory disorders
|
|
DE102005037844A1
(de)
|
2005-08-04 |
2007-04-05 |
Intendis Gmbh |
Wasserfreies Mehr-Phasen-Gel-System
|
|
CN101287835A
(zh)
|
2005-08-17 |
2008-10-15 |
株式会社百奥尼 |
用于siRNA细胞内输送的siRNA-亲水性聚合物结合物及其方法
|
|
WO2007030167A1
(en)
|
2005-09-02 |
2007-03-15 |
Nastech Pharmaceutical Company Inc. |
Modification of double-stranded ribonucleic acid molecules
|
|
FR2890859B1
(fr)
|
2005-09-21 |
2012-12-21 |
Oreal |
Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
|
|
AU2006306228A1
(en)
|
2005-10-24 |
2007-05-03 |
University Of Massachusetts |
Compositions and their uses for gene therapy of bone conditions
|
|
FR2894582B1
(fr)
|
2005-12-12 |
2008-02-22 |
Fabre Pierre Dermo Cosmetique |
Sirna anti myosine va et depigmentation de la peau
|
|
EP1968643A2
(en)
|
2005-12-16 |
2008-09-17 |
Diatos |
Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
|
|
JP2009522303A
(ja)
|
2005-12-30 |
2009-06-11 |
ウェイ−ウー ヒー， |
瘢痕を生じない皮膚創傷治癒を促進するｓｉＲＮＡ組成物および創傷処置の方法
|
|
US20070231392A1
(en)
|
2006-01-23 |
2007-10-04 |
Ernst Wagner |
CHEMICALLY MODIFIED POLYCATION POLYMER FOR siRNA DELIVERY
|
|
AU2007212700A1
(en)
|
2006-01-26 |
2007-08-16 |
University Of Massachusetts |
RNA interference agents for therapeutic use
|
|
LT2712618T
(lt)
|
2006-06-23 |
2017-02-27 |
Engeneic Molecular Delivery Pty Ltd. |
Vaistų, terapinių nukleorūgščių ir funkcinių nukleorūgščių tikslinis įvedimas į žinduolio ląsteles per nepažeistas žuvusias bakterines ląsteles
|
|
US20080039415A1
(en)
|
2006-08-11 |
2008-02-14 |
Gregory Robert Stewart |
Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
|
|
CN101500548A
(zh)
|
2006-08-18 |
2009-08-05 |
弗·哈夫曼-拉罗切有限公司 |
用于体内递送多核苷酸的多缀合物
|
|
US7872118B2
(en)
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
|
EP2081949B1
(en)
|
2006-09-22 |
2014-12-10 |
GE Healthcare Dharmacon, Inc. |
Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
|
|
US8039010B2
(en)
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
|
US8476243B2
(en)
|
2006-12-29 |
2013-07-02 |
Transderm, Inc. |
Methods and compositions for treating keratin hyperproliferative disorders
|
|
US8530436B2
(en)
|
2007-01-29 |
2013-09-10 |
Transderm, Inc. |
Methods and compositions for transdermal delivery of nucleotides
|
|
WO2008109353A1
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting map2k gene expression and uses thereof
|
|
WO2008109105A2
(en)
|
2007-03-06 |
2008-09-12 |
Flagship Ventures |
Methods and compositions for improved therapeutic effects with sirna
|
|
WO2008124634A1
(en)
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Polymer-encapsulated reverse micelles
|
|
US9884899B2
(en)
|
2007-07-06 |
2018-02-06 |
Promedior, Inc. |
Methods for treating fibrosis using CRP antagonists
|
|
WO2009020344A2
(en)
|
2007-08-06 |
2009-02-12 |
Postech Acad Ind Found |
Small interfering rnas (sirnas) controlling multiple target genes and method for preparing the same
|
|
US20090043367A1
(en)
|
2007-08-09 |
2009-02-12 |
Yitzhak Zilberman |
Apparatus and methods for removing an electronic implant from a body
|
|
EP3121281B1
(en)
|
2007-08-27 |
2021-03-31 |
1Globe Health Institute LLC |
Compositions of asymmetric interfering rna and uses thereof
|
|
WO2009045457A2
(en)
|
2007-10-02 |
2009-04-09 |
Rxi Pharmaceuticals Corp. |
Tripartite rnai constructs
|
|
CA2701845A1
(en)
|
2007-10-03 |
2009-04-09 |
Quark Pharmaceuticals, Inc. |
Novel sirna structures
|
|
US7935816B2
(en)
|
2007-10-25 |
2011-05-03 |
Gene Tools, Llc |
Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
|
|
EP2229186A2
(en)
|
2007-12-04 |
2010-09-22 |
Alnylam Pharmaceuticals Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
KR100949791B1
(ko)
|
2007-12-18 |
2010-03-30 |
이동기 |
오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
|
|
CA2713379A1
(en)
|
2008-01-31 |
2009-11-05 |
Alnylam Pharmaceuticals, Inc. |
Optimized methods for delivery of dsrna targeting the pcsk9 gene
|
|
EP3643782A1
(en)
|
2008-02-11 |
2020-04-29 |
Phio Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
|
US8575123B2
(en)
|
2008-04-11 |
2013-11-05 |
Tekmira Pharmaceuticals Corporation |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
WO2009132050A2
(en)
|
2008-04-21 |
2009-10-29 |
Otonomy, Inc. |
Auris formulations for treating otic diseases and conditions
|
|
US20110218334A1
(en)
|
2008-07-11 |
2011-09-08 |
Alnylam Pharmaceuticals, Inc. |
PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
|
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
|
CA2731779A1
(en)
|
2008-07-24 |
2010-01-28 |
Rxi Pharmaceuticals Corporation |
Rnai constructs and uses therof
|
|
CN107083386A
(zh)
|
2008-08-25 |
2017-08-22 |
埃克斯雷德制药有限公司 |
阻止结缔组织生长因子的反义核苷酸及其用途
|
|
EP2334319B1
(en)
|
2008-08-25 |
2017-12-06 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to ctgf
|
|
US8946172B2
(en)
|
2008-08-25 |
2015-02-03 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to CTGF
|
|
WO2010027830A2
(en)
|
2008-08-25 |
2010-03-11 |
Excaliard Pharmaceuticals, Inc. |
Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases
|
|
EP2342340A1
(en)
|
2008-09-22 |
2011-07-13 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
|
WO2010039543A2
(en)
|
2008-09-23 |
2010-04-08 |
Traversa Therapeutics, Inc. |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
|
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
|
JP5832293B2
(ja)
|
2008-12-04 |
2015-12-16 |
オプコ ファーマシューティカルズ、エルエルシー |
血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法
|
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
CA2762095A1
(en)
|
2009-05-16 |
2010-11-25 |
Kunyuan Cui |
Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules
|
|
US8486909B2
(en)
|
2009-06-24 |
2013-07-16 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
|
|
KR101801407B1
(ko)
*
|
2009-07-24 |
2017-11-24 |
큐알엔에이, 인크. |
시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
|
|
US8227444B2
(en)
|
2009-12-04 |
2012-07-24 |
Opko Ophthalmics, Llc |
Compositions and methods for inhibition of VEGF
|
|
EP2542058B1
(en)
|
2010-03-02 |
2018-10-10 |
RXi Pharmaceuticals Corporation |
Effective sensitizing dose of a gelled immunomodulating topical composition
|
|
WO2011119852A1
(en)
*
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
|
US9095504B2
(en)
|
2010-03-24 |
2015-08-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in ocular indications
|
|
CA2794189C
(en)
|
2010-03-24 |
2022-01-11 |
Rxi Pharmaceuticals Corporation |
Rna interference in dermal and fibrotic indications
|
|
DK2670411T3
(da)
|
2011-02-02 |
2019-05-13 |
Excaliard Pharmaceuticals Inc |
Antisense-forbindelser rettet mod bindevævsvækstfaktor (CTGF) til anvendelse i en fremgangsmåde til behandling af keloider eller hypertrofiske ar
|
|
EP2725103A3
(en)
|
2011-11-14 |
2016-01-06 |
Silenseed Ltd |
Methods and compositions for treating prostate cancer
|
|
US20140072613A1
(en)
|
2012-09-10 |
2014-03-13 |
Cynthia Lander |
Compositions and Methods for Treating Cutaneous Scarring
|
|
EP2719762A1
(de)
|
2012-10-11 |
2014-04-16 |
Secutech International Pte. Ltd. |
Tyrosinaseinhibitoren zur Depigmentierung oder Haarentfernung
|
|
WO2014076703A1
(en)
|
2012-11-14 |
2014-05-22 |
Silenseed Ltd. |
Methods and compositions for treating cancer
|
|
WO2015038892A1
(en)
|
2013-09-13 |
2015-03-19 |
Moderna Therapeutics, Inc. |
Polynucleotide compositions containing amino acids
|
|
JP6772062B2
(ja)
|
2013-12-02 |
2020-10-21 |
フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． |
癌の免疫療法
|
|
WO2015085113A1
(en)
|
2013-12-04 |
2015-06-11 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of wound healing utilizing chemically modified oligonucleotides
|
|
CA2947270A1
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
|
CA2947619A1
(en)
|
2014-05-01 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
|
EP3188799B1
(en)
|
2014-09-05 |
2022-07-06 |
Phio Pharmaceuticals Corp. |
Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
|
|
WO2016090173A1
(en)
*
|
2014-12-03 |
2016-06-09 |
Rxi Pharmaceuticals Corporation |
Methods for the treatment of alopecia areata utilizing gene modulation approaches
|
|
RS60762B1
(sr)
|
2015-04-03 |
2020-10-30 |
Univ Massachusetts |
Oligonukleotidna jedinjenja za ciljane irnk hantingtina
|
|
WO2016161378A1
(en)
|
2015-04-03 |
2016-10-06 |
University Of Massachusetts |
Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
|
|
EP3929293A3
(en)
|
2015-04-03 |
2022-03-16 |
University Of Massachusetts |
Fully stabilized asymmetric sirna
|
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
|
US11001845B2
(en)
|
2015-07-06 |
2021-05-11 |
Phio Pharmaceuticals Corp. |
Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
|
|
CA2997949A1
(en)
|
2015-09-11 |
2017-03-16 |
Rxi Pharmaceuticals Corporation |
Methods for treating skin disorders and conditions utilizing haptens
|
|
US11021707B2
(en)
|
2015-10-19 |
2021-06-01 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
|
|
WO2017173453A1
(en)
|
2016-04-01 |
2017-10-05 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
|
JP7167059B2
(ja)
|
2017-04-19 |
2022-11-08 |
フィオ ファーマシューティカルズ コーポレーション |
核酸化合物の局所送達
|
|
CN111201024A
(zh)
|
2017-08-07 |
2020-05-26 |
菲奥医药公司 |
经化学修饰的寡核苷酸
|
|
CA3160657A1
(en)
|
2019-11-08 |
2021-05-14 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
|
|
WO2021138537A1
(en)
|
2019-12-31 |
2021-07-08 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides with improved systemic delivery
|
|
WO2023015265A2
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides
|
|
WO2023015264A1
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
|
|
WO2023130021A1
(en)
|
2021-12-30 |
2023-07-06 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides with improved delivery properties
|
|
WO2024064769A1
(en)
|
2022-09-21 |
2024-03-28 |
Phio Pharmaceuticals Corp. |
Induction of stem-like activated t cells
|
|
AU2023472921A1
(en)
|
2023-11-08 |
2026-05-21 |
Phio Pharmaceuticals Corp. |
Intratumoral targeting of pd-1
|
|
CN122477046A
(zh)
|
2023-11-28 |
2026-07-28 |
菲奥医药公司 |
利用RNAi的增强的组合免疫检查点抑制治疗
|